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Acute kidney injury (AKI) and chronic kidney disease (CKD) are the most severe
consequences of kidney injury. They are interconnected syndromes as CKD
predisposes to AKI and AKI may accelerate CKD progression. Despite their growing
impact on the global burden of disease, there is no satisfactory treatment for AKI and
current therapeutic approaches to CKD remain suboptimal. Recent research has focused
on the therapeutic target potential of epigenetic regulation of gene expression, including
non-coding RNAs and the covalent modifications of histones and DNA. Indeed, several
drugs targeting histone modifications are in clinical use or undergoing clinical trials. Acyl-
lysine histone modifications (e.g. methylation, acetylation, and crotonylation) have
modulated experimental kidney injury. Most recently, increased histone lysine
crotonylation (Kcr) was observed during experimental AKI and could be reproduced in
cultured tubular cells exposed to inflammatory stress triggered by the cytokine TWEAK.
The degree of kidney histone crotonylation was modulated by crotonate availability and
crotonate supplementation protected from nephrotoxic AKI. We now review the functional
relevance of histone crotonylation in kidney disease and other pathophysiological
contexts, as well as the implications for the development of novel therapeutic
approaches. These studies provide insights into the overall role of histone crotonylation
in health and disease.
Keywords: acute kidney injury, chronic kidney disease, epigenetics, crotonylation, histone posttranslational
modification, histone deacetylase, TWEAK, nephrotoxicityINTRODUCTION: AKI AND CKD
Acute kidney injury (AKI) and chronic kidney disease (CKD) are the most severe consequences of
kidney injury. AKI is commonly defined by a sudden (within 48 h) increase in serum creatinine and
is usually transient (Kidney Disease, 2012). However, it may be as severe as to require renal
replacement therapy and is associated with an increased risk of death. CKD is defined by
abnormalities of kidney structure or function that persist for longer than three months and havein.org April 2020 | Volume 11 | Article 3931
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et al., 2019). CKD may progress to end-stage kidney disease
requiring renal replacement therapy and is associated with an
increased risk of premature death. Indeed, CKD was among the
fastest growing causes of death worldwide and it is estimated that
it will become the second most common cause of death within
the next century in some countries (Ortiz et al., 2019). AKI and
CKD are considered interconnected syndromes, as CKD
predisposes to AKI and AKI may accelerate CKD progression
(Chawla et al., 2014). AKI was thought to be followed by
complete recovery of kidney structure or function. However,
the repair process may be unsuccessful leading to engagement of
pathways promoting transition to CKD. In this regard AKI and
CKD share a number of pathogenic processes, including
inflammation and parenchymal cell death. Additionally, kidney
injury during AKI may initiate or aggravate the processes of
capillary rarefaction and fibrosis that characterize CKD (Kida
et al., 2013; Polichnowski, 2018; Yang et al., 2018). The clinical
care of patients with AKI or CKD is marred by a paucity of
effective therapeutic approaches. Thus, there is no therapy that
prevents or accelerates recovery from AKI. Additionally, only a
handful of drugs have been approved to slow the progression of
CKD, including renin-angiotensin system blockers for
proteinuric CKD and tolvaptan for polycystic kidney disease
(Perez-Gomez et al., 2015). However, they slow but do not
completely prevent CKD progression and do not promote
regression. Thus, novel therapeutic approaches should be
developed based on an improved understanding of the cellular
and molecular pathogenesis of AKI and CKD and of the drivers
of the AKI-to-CKD transition.EPIGENETIC REGULATION OF GENE
EXPRESSION
Epigenetic regulation refers to mechanisms that control gene
expression without altering the nucleotide sequence. In general,
epigenetic modifications are heritable during cell division
although they are reversible and could be altered by age,
disease, and environment. Epigenetic regulators include non-
coding RNAs, and covalent modifications of histones and DNA.
Histone modifications involve proteins responsible for the
addition (writer), recognition (reader), and removal (eraser) of
modifiers such as acyl-lysine modifications.
The main modification on DNA is methylation catalyzed by
DNA methyltransferases (DNMTs). These are enzymes that
methylate the 5-cytosine of CpG dinucleotides, frequently
located in the first exons or near promoters (Mohtat and
Susztak, 2010). DNA promoter methylation is a silencing
mechanism that inhibits transcription factor binding through
chromatin packaging or repressor recruitment (Beckerman
et al., 2014).
Histones are positively charged and they associate with
negatively charged DNA to package in condensed chromatin
and form nucleosomes, which are the basic units of chromatin.
Nucleosomes pack 147 DNA base pairs around a histoneFrontiers in Pharmacology | www.frontiersin.org 2octamer composed of two H3-H4 histone dimers stabilized as
a tetramer which is flanked by two separate H2A-H2B dimers
(Luger et al., 1997; Davey et al., 2002). Histone 1 (H1) acts as a
linker and completes the chromatosome by protecting
internucleosomal linker DNA (Campos and Reinberg, 2009).
There are more than 100 types of histone modifications which
regulate gene expression, such as methylation, acetylation,
phosphory la t ion , crotony la t ion , sumoyla t ion , and
ubiquitination (Susztak, 2014). However, the biological
function of most of these modifications remains unknown. The
best characterized consist of addition of acyl groups to specific
amino acids, resulting in methylation, acetylation and
crotonylation of lysine residues on histone H3.
Histone methylation requires the transfer of methyl groups to
histone lysine or arginine residues by histone methyltransferases.
Lysine residues can accept up to three methyl groups, resulting in
mono-, di-, or trimethylated lysine, and arginine can accept up to
two methyl groups, resulting in mono- or dimethylated arginine.
Methyl groups can be removed by histone demethylases (Morera
et al., 2016). The addition of methyl groups does not change
histone charge, rather provides platforms for binding of
transcription factors that may stimulate or suppress gene
expression (Nguyen and Zhang, 2011).
Histone acetylation, the transfer of an acetyl group to lysine
residues, changes the charge of histones and favors chromatin
relaxation, facilitating binding of transcription factors to
promoters and gene expression (Ramakrishnan and Pili, 2013).
Histone acetylation is catalyzed by histone acetyltranferases
(HAT) and it is reversible when histone deacetylases (HDAC)
remove acetyl groups.
Histone lysine crotonylation (Kcr) was more recently
described and consists in the transfer of crotonyl groups to
lysine residues of histones, also conferring them negative charge
(Tan et al., 2011). Recently, a role of histone Kcr was described in
AKI (Ruiz-Andres et al., 2016a). We now review the functional
relevance of histone crotonylation in tissue physiopathology with
emphasis in kidney disease and the implications for the
development of novel therapeutic approaches.EPIGENETIC MODIFICATIONS IN RENAL
INJURY
Both AKI and CKD are associated with cell death, inflammation,
and diverse degrees of fibrosis. All of these could be regulated by
epigenetic modifications. DNA methylation and histone
acetylation and methylation are the most studied epigenetic
mechanisms in renal injury, and evidence supports their
functional relevance for kidney disease (Table 1).
Global kidney DNAmethylation was reduced in experimental
AKI induced by ischemia-reperfusion injury (IRI) or cisplatin,
and this was associated to the expression of inflammatory genes
(Guo et al., 2017; Zhao et al., 2017). In this regard, DNA
methylation contributes to silencing the expression of the
nephroprotective genes Klotho (which has anti-inflammatory
and anti-fibrotic properties) and RASAL1 (which has anti-April 2020 | Volume 11 | Article 393
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or pharmacological inhibition decreased fibrosis and prevented
the AKI-to-CKD transition in part because of preserved
expression of Klotho and RASAL1 (Bechtel et al., 2010; Sun
et al., 2012; Tampe et al., 2017).
Histone methylation, depending on context, lysine residue or
extent of methylation may activate or repress gene transcription.
Overall kidney histone methylation was increased in preclinical
CKD induced by unilateral ureteral obstruction (UUO) or
diabetic nephropathy [reviewed in (Fontecha-Barriuso et al.,
2018)]. In this regard, the expression of the histone methyl-
transferase, EZH2, is increased in UUO and in CKD patients and
its pharmacological inhibition reduced preclinical fibrosis (Zhou
et al., 2016). Similar results were found for the histone methyl-
transferase, SMYD2 in clinical and preclinical PKD (Li et al.,
2017). In AKI induced by IRI or endotoxin, increased histone
methylation has been linked to the increased expression of pro-
inflammatory and pro-fibrotic genes (Naito et al., 2008; Zager
and Johnson, 2009). Moreover, histone methylation in the MCP1
and NGAL genes was detected in urine from AKI patients
(Munshi et al., 2011).
Histone acetylation generally favors gene expression and it
has been extensively studied in renal injury. Global changes in
kidney histone acetylation were observed in experimental AKI
(e.g. IRI, endotoxemia) and CKD (UUO, diabetic nephropathy).
Histone acetylation increased during renal injury in most animal
models analyzed (endotoxemia, UUO, diabetic nephropathy in
db/db mice) (Sayyed et al., 2010; Huang et al., 2015; HewitsonFrontiers in Pharmacology | www.frontiersin.org 3et al., 2017). During ischemia reperfusion injury (IRI), histone
acetylation presents a more complex regulation, it is transiently
decreased during ischemia, but it recovers, or even increases,
after reperfusion, and may persist increased for 3 weeks
(Marumo et al., 2008; Zager et al., 2011). The impact of
histone acetylation over the expression of specific relevant
genes in AKI has been also studied, including the
nephroprotective genes PGC1a and Klotho, 3-hydroxy-3-
methyl-g lutary l-CoA reductase (HMGCR) and the
inflammatory cytokine Interleukine-6 (IL-6), among others
(Naito et al., 2009; Li et al., 2010; Ruiz-Andres et al., 2016b).
The functional contribution of histone acetylation to kidney
injury is supported by numerous preclinical studies in AKI
(e.g. cisplatin, IRI) and CKD [e.g. UUO, polycystic kidney
disease (PKD), diabetic nephropathy] models, and HDAC
inhibitors were frequently nephroprotective (Fontecha-Barriuso
et al., 2018). Related with histone acetylation, another emergent
line of research is the study of the bromodomain and
extraterminal (BET) protein family. BET proteins are readers
that bind to acetylated lysines of histones and facilitate binding of
transcription factors. BET targeting has been beneficial in
preclinical kidney disease and ongoing clinical trials of the
BET inhibitor apabetalone explore kidney function as a
secondary outcome (Suarez-Alvarez et al., 2017; Fontecha-
Barriuso et al., 2018).
These data show the complex regulation of epigenetic
modifications in kidney diseases. The overall pattern of the
different DNA and histone marks suggests that epigeneticTABLE 1 | Examples of changes in the overall pattern of DNA methylation or histone modifications during kidney disease.
Epigenetic modification Overall levels in kidney Reference
DNA methylation (-CH3): Overall increase in:
• peripheral blood leukocytes from inflamed CKD G5 patients
• kidney in RASAL1 genes in mouse model of folic acid-induced fibrosis
• kidney in Klotho gene in mouse model of adenine-induced CKD
(Hunag et al., 2012; Ko et al., 2013; Zhao
et al., 2017)
Overall decrease in:
• kidney in experimental AKI induced by IRI
• kidney in tubules of CKD patients
(Stenvinkel et al., 2017; Bechtel et al.,




• kidney in experimental renal fibrosis induced by UUO
• kidney in diabetic nephropathy in uninephrectomy db/db mice
(Sayyed et al., 2010; Zhou et al., 2016;
Hewitson et al., 2017)
Overall decrease in:
• kidney in db/db mice
• kidney in uninephrectomy C57BL/6 mice




• kidney in experimental AKI-CKD transition induced by IRI
• kidney in experimental renal fibrosis induced by UUO
• kidney in diabetic nephropathy in uninephrectomy db/db mice
(Sayyed et al., 2010; Zager et al., 2011;
Hewitson et al., 2017)
Overall decrease in:
• kidney: early decrease in severe IRI AKI, and recovery during reperfusion
• kidney in db/db mice




• kidney in experimental nephrotoxic AKI by folic acid
Changes in specific histones
• peripheral blood mononuclear cells from IgA nephropathy patients: increased
(HIST1H2AC, HIST1H4A, and decreased HIST1H1B)
(Ruiz-Andres et al., 2016; Lin et al., 2020)In parenthesis, modified amino acid (K, lysine; R, arginine) and the residue added.
AKI, acute kidney injury; CKD, chronic kidney disease; Kcr, crotonylation; IRI, ischemia-reperfusion injury; UUO, unilateral ureteral obstruction.April 2020 | Volume 11 | Article 393
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observed in kidney disease, opening the door for therapeutic
strategies targeting epigenetic modulation.HISTONE CROTONYLATION
The application of high-sensitivity mass spectrometry techniques
recently identified lysine crotonylation (Kcr) as a novel histone
lysine acylation (Tan et al., 2011). Histone crotonylation
represents an evolutionarily conserved histone mark which
consists in the addition of a crotonyl group from crotonyl-
coenzyme A to lysine residues, that similar to acetylation,
modifies the charge of the histones (Tan et al., 2011; Fontecha-
Barriuso et al., 2018). Nonetheless, the genomic pattern and
function of histone crotonylation differs from histone acetylation
(Tan et al., 2011). Histone crotonylation mainly marks active
promoters and potential enhancers, but the impact on gene
expression is unclear, as it can activate or repress gene
transcription (Tan et al., 2011; Fellows et al., 2018).
Histone Crotonyltranferases
Histone crotonylation shares enzyme regulators with histone
acetylation. Specifically, the histone acetyltransferase CBP/P300
provides the bulk of histone crotonyltransferase (HCT) (also
termed histone crotonylase) activity in mammalian cells (Liu X.
et al., 2017). The evolutionary conserved MOF, from the MYST
family of histone acetyltransferases, also has HCT activity, as
well as its yeast homologue (Esa1) (Chen et al., 2015; Liu X.
et al., 2017). Additionally, similar to other lysine acylations,
histone crotonylation has been proposed to occur non-
enzymatically (Wagner and Hirschey, 2014; Sabari et al.,
2017). The enzymatic activity of CBP/P300 over crotonylation
or acetylation depends on the levels of the precursors acetyl-
CoA and crotonyl-CoA. Since intracellular acetyl-CoA is more
abundant that crotonyl-CoA, the rate of crotonylation is more
sensitive to changes of precursor levels (Sabari et al., 2015). In
this line, while global histone acetylation is not affected by
changes of sodium acetate availability, the levels of global
histone crotonylation dramatically increase with increasing
levels of sodium crotonate. This has physiological relevance,
since crotonate addition also promotes gene expression in vivo
and in vitro (Sabari et al., 2015; Ruiz-Andres et al., 2016a).
Crotonate, the short-chain fatty acid (SCFA) precursor of
crotonyl-CoA, is mainly produced by the colon microbiota
(Stilling et al., 2016). Circulating SCFA (acetate, crotonate,
butyrate, and propionate) are taken up by tissues and
converted into acyl-CoA by the acyl-CoA Synthetase Short
Chain Family Member 2 (ACSS2) or eventually yield
crotonyl-CoA through different metabolic pathways such as
fatty acid b-oxidation (Sabari et al., 2015; Rivière et al., 2016)
(Figure 1). In this line, microbiota depletion decreases histone
crotonylation in colon supporting the concept that microbiota
may modulate epigenetic modifications (Fellows et al., 2018).
Additionally, intracellular acetyl-CoA, generated during
glycolysis, may also influence the extent of histoneFrontiers in Pharmacology | www.frontiersin.org 4crotonylation. Under conditions of acetyl-CoA depletion,
caused either by low glucose levels or by glucose carbons
being directed away from ATP citrate lyase (ACL), other
acyl-CoAs, such as crotonyl-CoA, will face less competition
for acyl-transferase activity and this could also lead to
epigenetic changes (Sabari et al., 2017).
Kcr Readers
Histone covalent modifications are recognized by chromatin-
binding protein modules, so-called “readers”. Acetyl lysine (Kac)
residues are recognized mainly by bromodomains, YEATS
domains, and double PHD-finger domains (DPF) (Liu X. et al.,
2017). Bromodomains barely have affinity for long acyl
modifications like Kcr sites (Andrews et al., 2016), although
TAF1 can recognize them with low affinity (Flynn et al., 2015).
By contrast, the evolutionarily conserved YEATS domain is a
family of Kcr readers in yeast (Andrews et al., 2016). Indeed,
YEATS domain human proteins YEATS2 and AF9 have higher
affinity for Kcr sites than for shorter acyl-groups such as acetyl
(Li et al., 2016; Zhao et al., 2016). Likewise, DPF family proteins
MOZ and DPF2 recognize a wide range of histone lysine
acylations with a strong preference for Kcr (Xiong et al., 2016).
Histone Decrotonylases
HDACs also have decrotonylase activity. In mammals, there are
11 metal-dependent HDACs divided into class I (HDACs 1–3,
8), class II (HDAC 4–7, 9, 10), and class IV (HDAC 11) and
seven sirtuins (Sirt1-7) (Lin et al., 2012; Lee, 2013). Class I
HDACs are the main histone decrotonylases (Wei et al., 2017a).
HDAC inhibitors such as suberoylanilide hydroxamic acid
(SAHA, vorinostat) may enhance Kcr by inhibiting class I
HDACs (Wu et al., 2017). The 3 µM vorinostat concentration
used in these studies is within the range reached in vivo during
the therapeutic use of the drug in humans (1.2 ± 0.62 µM)
(https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/
021991s002lbl.pdf). HDAC1/2 containing complexes are critical
regulators of histone Kcr (Kelly et al., 2018). Thus, genetic
deletion of HDAC1/2 reduced total decrotonylase activity by
85%. Differences from prior studies could be related to the
analysis of cells (Kelly et al., 2018) rather than of recombinant
enzymes in vitro that described HDC3 decrotonylase activity
(Tan et al., 2011; Madsen and Olsen, 2012), although there is the
distinct possibility that different enzymes are more important in
different cell types and environmental contexts. The histone
decrotonylase activity of HDACs allows a further mechanism
by which microbiota could increase crotonylation: generation of
butyrate, an HDAC inhibitor (Shimazu et al., 2013). Although
Sirt1 and Sirt3 have robust deacetylase activity (Houtkooper
et al., 2012), they can also catalyze the hydrolysis of lysine
crotonylated histones, but only Sirt3 regulates Kcr dynamics
and gene transcription in living cells (Bao et al., 2014).
Other Regulators of Kcr
There are additional pathways that may regulate Kcr.
Chromodomain Y-like (CDYL) negatively regulates histone
crotonylation acting as a crotonyl-CoA hydratase that converts
crotonyl-CoA required for Kcr into b-hydroxybutyryl-CoA.April 2020 | Volume 11 | Article 393
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Given the overlap between some Kcr and Kac sites in histones
and shared modulators, initial concerns were raised as to the
relevance of Kcr. It is now clear that Kcr and Kac are
mechanistically and functionally different. Kcr is critically
important for global transcription in mammalian cells
(Wei et al., 2017b). Specifically, in both human somatic and
mouse male germ cell genomes, histone Kcr marks either activeFrontiers in Pharmacology | www.frontiersin.org 5promoters or potential enhancers (Tan et al., 2011). Kcr but not
Kac preferentially marked “escapee genes” during post-meiotic
sex inactivation in mouse testis (Montellier et al., 2012).
Moreover, p300-catalyzed histone crotonylation directly
stimulates transcription to a greater degree than histone
acetylation (Sabari et al., 2015). Furthermore, CBP/p300
mutants may be deficient in HAT activity but competent for
HCT activity (Liu X. et al., 2017). Indeed, YEATS domains andFIGURE 1 | Histone crotonylation: enzymes and modulators. The gut microbiota is a source of short chain fatty acids (SCFAs) that inside cells may be metabolized
to acetyl-CoA or crotonyl-CoA. These are the precursors that enzymes may use to promote lysine acetylation (Kac) or lysine crotonylation (Kcr) of histone and non-
histone proteins. Crotonylated proteins have now been found within the nucleus and the cytoplasm. Already characterized crotonyltransferases (also termed
crotonylases) include CBP/P300 and MOF, while histone decrotonylases include some histone deacetylases (HDAC) and sirtuin 3 (Sirt3). Kcr readers, proteins that
identify Kcr in histones, include YEATS domain human proteins YEATS2 and AF9 as well as DPF family proteins MOZ and DPF2. Chromodomain Y-like (CDYL)
negatively regulates histone crotonylation acting as a crotonyl-CoA hydratase that converts crotonyl-CoA required for Kcr into b-hydroxybutyryl-CoA. TCA,
tricarboxylic acid; ACL, ATP citrate lyase; ACCS2, acyl-CoA Synthetase Short Chain Family Member 2.April 2020 | Volume 11 | Article 393
Martinez-Moreno et al. Histone Crotonylation and KidneyDPF proteins showed a greater affinity for Kcr over Kac and by
two different molecular mechanisms (Li et al., 2016; Xiong et al.,
2016). Finally, Kcr are more resistant to deacetylases than Kac,
offering a better chance to resist repression and enabling a robust
and productive transcription (Rousseaux and Khochbin, 2015).HISTONE CROTONYLATION IN NON-
RENAL TISSUES
Histone crotonylation was initially well characterized in human
somatic and male germ cells (Tan et al., 2011). Recently, histone
crotonylation has been observed in different cells and tissues but
its function over gene expression has been only explored outside
the kidney in gametogenesis, reprogramming of pluripotent
stem-cells and colon epithelial cells.Gametogenesis and Pluripotent Stem
Cells
Histone crotonylation, but not acetylation, is a specific mark of
active promoters or potential enhancers of sex chromosomes-linked
genes in male haploid cells immediately following meiosis and is
associated with the release of transcriptional repressors in such sex
chromosomes, which is considered an important element in the
programming of the genome in the postmeiotic phase of
spermatogenesis (Tan et al., 2011; Montellier et al., 2012). In this
regard, CDYL decreased histone crotonylation and also sperm
motility and fertility in mice (Liu S. et al., 2017). Histone
crotonylation also favors the activation of pluripotency-inducing
genes, maintenance of telomeres, and cell reprogramming during
the chemical induction of pluripotent stem cells (CiPSCs) (Fu et al.,
2018). In this line, in embryonic stem cells, Kcr and the expression
of genes required for pluripotency were decreased by overexpression
of mutant HDACs with impaired HDAC function but intact
histone decrotonylase activity (Wei et al., 2017a).Gut Cells
In colon epithelial cells, crotonylated histones, more concretely
H3K18cr, was associated to transcription start sites of genes
involved in cancer, suggesting that deregulation of histones
crotonylation may be linked to cancer. Butyrate from gut
microbiota inhibited HDACs with decrotonylase activity, thus
modifying the level of gut histone crotonylation and linking the
gut microbiota with local tissue histone crotonylation (Fellows et al.,
2018). In addition, microbiota depletion resulted in increased
expression of HDAC2 (Fellows et al., 2018), an enzyme with
decrotonylase activity and also related to tumorigenesis in colon
cancer (Zhu et al., 2004) and with the progression from adenoma to
carcinoma (Ashktorab et al., 2009). Several cancer-associated
proteins are subject to Kcr by CBP/p300 (Huang et al., 2018). On
the other hand, HDAC inhibitors induce the intestinal mucosa
expression of ACSS2, which favors latent HIV reactivation through
histone crotonylation (Jiang et al., 2018).Frontiers in Pharmacology | www.frontiersin.org 6LYSINE CROTONYLATION BEYOND
HISTONES
Kcr has been identified in non-histone proteins. Studies using
specific antibody enrichment followed by high resolution mass
spectrometry and intensive bioinformatics analysis have
demonstrated that Kcr occurs in a large number of proteins,
predominantly in nuclei, but also in the cytoplasm (Wei et al.,
2017b; Wu et al., 2017; Xu et al., 2017). Crotonylation was
promoted by exposure to crotonate or CBP/p300 overexpression
(Wei et al., 2017b). Crotonylated non-histone proteins have been
characterized in different cell types such as Hela cells, H1299 cells
(Wei et al., 2017b; Xu et al., 2017), HTC 116 (Huang et al., 2018),
and in tissues such as lung, kidney, liver, colon, uterus, ovary,
and brain of mice (Tweedie-Cullen et al., 2012; Xu et al., 2017).
Crotonylation of non-histone proteins is thought to be
important in various biological processes, such as RNA
splicing, gene expression, chromatin organization, nucleic acid
metabolism, and the cell cycle (Wei et al., 2017b). However, the
requirement of crotonylation for most of these putative cellular
functions has not been formally tested. HDAC1 is among the
crotonylated non-histone proteins in HELA cells treated with
crotonate and HDAC1 crotonylation leads to a reduced
deacetylase activity (Wei et al., 2017b).HISTONE CROTONYLATION IN KIDNEY
INJURY
Kidney injury is probably the best characterized disease
condition so far in terms of extent and function of histone
crotonylation (Justo et al., 2006) (Figure 2). Histone Kcr was
observed in tubular cells from healthy mouse and human kidney
and nephrotoxic AKI was associated with a global increase in
kidney histone crotonylation (Ruiz-Andres et al., 2016a).
Likewise, in cultured proximal tubule epithelial cell cultures,
stimulation with the proinflammatory cytokine TWEAK, a
driver of kidney injury (Sanz et al., 2008; Ruiz-Andres et al.,
2015), increased global histone Kcr (Ruiz-Andres et al., 2016a).
Additionally, crotonate supplementation increased global
histone Kcr in cultured tubular cells and in the kidneys in vivo.
Thus, levels of histone crotonylation in kidney tubular cells may
be modified by cell stress or by crotonate administration.
The increased histone crotonylation in cells stimulated with
TWEAK and in AKI kidneys was associated with decreased
PGC1a and Sirt-3 expression and with increased CCL2
expression, a chemokine which contributes to kidney
inflammation (Ruiz-Andres et al., 2016a). PGC1a and Sirt-3
have nephroprotective actions (Kong et al., 2010; Morigi et al.,
2015; Fontecha-Barriuso et al., 2019). Besides, Sirt3 and PGC1a
regulate each other. PGC1a is a transcription factor and a major
regulator of gluconeogenesis, as well as driver of mitochondrial
biogenesis, and Sirt3 is a mediator of the effect of PGC1a on
mitochondrial biogenesis (Van Beneden et al., 2011). The
increased histone crotonylation induced by crotonateApril 2020 | Volume 11 | Article 393
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resulted in an increased PGC1a and sirtuin-3 expression, as
well as a decrease of CCL2 expression. That is, the systemic
administration of crotonate prevents the decrease of PGC1a and
sirtuin-3 expression, and the increase of CCL2 expression in
mice with AKI and this was associated to protection from
experimental nephrotoxic AKI and preservation of renal
function (Justo et al., 2006). Taken together, the cell culture
evidence that crotonate increased histone crotonylation and
prevented proinflammatory responses while preserving
nephroprotective gene expression, the fact that it had similar
actions in vivo in AKI and that it protected from AKI, suggests
that crotonate may have a potential therapeutic effect on kidneyFrontiers in Pharmacology | www.frontiersin.org 7damage, and more specifically in AKI, by increasing histone
crotonylation. If this hypothesis is correct, then the spontaneous
global increase in histone crotonylation during AKI may be
considered part of an adaptive mechanism, even allowing for
potential discrepant level of crotonylation in specific genes. In
this regard, the previously described beneficial effects of HDAC
inhibitors such as valproic acid or trichostatin, in kidney damage
(Moreno et al., 2011; Van Beneden et al., 2013), should be viewed
in the context of their potential to induce histone crotonylation
(Madsen and Olsen, 2012; Wei et al., 2017a; Kelly et al., 2018)
and not just through the light of their impact on histone lysine
acetylation. Some examples of beneficial effects of HDAC
inhibitors that have been ascribed to modulation of histoneFIGURE 2 | Role of histone crotonylation in acute kidney injury (AKI). The figures depict the different stages of kidney injury and the integration of spontaneous
histone crotonylation or therapeutic drug-induced histone crotonylation. (A) Triggers of kidney injury, such as diverse forms of cell stress, including the
proinflammatory cytokine TWEAK, cause lethal or sublethal (e.g. decreased expression of the master regulator of mitochondrial biogenesis PGC1a or sirtuin 3, Sirt3)
kidney cell injury and elicit a proinflammatory response (e.g. chemokine synthesis) (Morigi et al., 2015; Martin-Sanchez et al., 2018; Fontecha-Barriuso et al., 2019).
(B) This will induce kidney injury that may be magnified by recruitment of inflammatory cells (Ruiz-Andres et al., 2016b). (C) During AKI, global kidney histone
crotonylation increases and this may be further increased by treatment with crotonate (Ruiz-Andres et al., 2016a). Decreased expression of decrotonylases, such as
Sirt3 may contribute to increased global histone crotonylation. Based on crotonate therapy results, we hypothesize that the overall impact of increased global histone
crotonylation supposes a brake in the kidney injury process, and, thus, a beneficial adaptive process. (D) As already indicated, treatment with crotonate improves
kidney injury and restores PGC1a or Sirt3 expression, decreasing chemokine production. Based on new knowledge of the therapeutic effects of HDAC inhibitors on
kidney injury in vivo and in culture (Chen et al., 2018; Fernandez-Fernandez et al., 2018), we now hypothesize that part of this beneficial effect of HDAC inhibitors
may be related to their role in crotonylation regulation, rather than or in addition to inhibition of deacetylase activity. (E) Eventually, either spontaneously or following
acceleration of recovery by therapy, kidney function recovers.April 2020 | Volume 11 | Article 393
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crotonylation include preservation of the expression of the
antiaging and nephroprotective gene Klotho despite the
presence of Klotho suppressors such as inflammatory cytokines
and albuminuria, and similar results were observed with PGC1a
expression (Chen et al., 2018; Fernandez-Fernandez et al., 2018;
Fontecha-Barriuso et al., 2019). This hypothesis should be
addressed through specifically designed experiments.
In peripheral blood mononuclear cells from dialysis patients
or healthy subjects, liquid chromatography–mass spectrometry
identified 347 crotonylated proteins (Lin et al., 2020). A total of
345 proteins were differentially expressed between hemodialysis
patients and controls, 93 of them upregulated and 252
downregulated. However, functional enrichment analysis did
not show significant differences between upregulated and
downregulated proteins and no direct relation was observed
between Kcr ratio and levels of expression.SUMMARY AND FUTURE PERSPECTIVES
In summary, histone lysine crotonylation is a recently described
posttranslational histone modification which, like previously
described ones, has the potential to regulated gene expression. To
date, its function in disease has been more extensively investigated
in kidney injury. AKI and tubular cell stress in culture are
characterized by increased global histone crotonylation. While it
is conceivable that this is the end-result of differential crotonylation
of many different genes, with very different impact on the expression
of these genes, supplementing crotonate both increased kidney
histone crotonylation and was nephroprotective and this was
associated with potential beneficial changes in the expression of
nephroprotective and proinflammatory genes. This opens the door
to explore therapeutic strategies based on the modulation of histone
crotonylation that, besides supplementing crotonate, may also
include modulation of the microbiota and the use of HDAC
inhibitors. In this regard the literature on the nephroprotective
effects of HDAC inhibition should be re-examined from the point of
view of their potential regulation of histone crotonylation. AFrontiers in Pharmacology | www.frontiersin.org 8detailed exploration of the role of histone crotonylation in kidney
disease may facilitate the study of its impact in health and disease of
other organs. Finally, the regulation and role of non-histone
crotonylation remains essentially unexplored. A recent manuscript
using a proteomics approach identified 155 upregulated and 198
downregulated crotonylated proteins in peripheral blood
mononuclear cells from IgA nephropathy patients, of which only
three were histones. Since only six patients were studied, whether
these changes are linked to IgA nephropathy itself, to CKD or to
other factors, remains unclear (Huang et al., 2012). In any case, this
manuscript identifies the potential of a systems biology approach
and eventual bioinformatics and machine learning analyses in
advancing the field. Thus, a systems biology analysis of the
impact of HDAC inhibitors in AKI may identify new biomarkers
or therapeutic targets.AUTHOR CONTRIBUTIONS
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